結直腸癌的個體化治療進展_《中國普外基礎與臨床雜志》

作者：

張洪偉 , 同李平 , 孫力

第四軍醫大學西京醫院，西京消化病醫院消化一科（西安 710032）;

關鍵詞：

結直腸癌個體化治療術前評估手術方式輔助化療

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

結直腸癌是一種嚴重威脅我國國民生命的惡性腫瘤，近年來其發病率呈不斷上升的趨勢。根據WHO報告的資料［1］顯示，我國結直腸癌死亡率2005年比1991年增加70.7%，年均增加4.71%。盡管對結直腸癌的病因學研究和以手術切除、放射治療和化學藥物治療為主的綜合治療取得了一定進展，但結直腸癌的治療仍然面臨巨大挑戰。對不同個體采用相同的治療方案不僅不能提高治療效果，而且造成醫療資源的浪費，甚至給患者帶來傷害。目前，個體差異與療效的關系越來越受到臨床醫生和研究者的重視。隨著循證醫學的不斷發展，結直腸癌的個體化治療日益成為臨床治療及基礎研究的重點。結直腸腫瘤多學科協作(multidisciplinary team，MDT)診治模式的運用為結直腸癌個體化診治提供了新的平臺［2］。....................

引用本文： 張洪偉,同李平,孫力. 結直腸癌的個體化治療進展. 中國普外基礎與臨床雜志, 2009, 16(9): 689-692. doi: 復制

1.	鄭樹主編. 結直腸腫瘤—基礎研究與臨床實踐 [M]. 北京: 人民衛生出版社， 2006: 3-4.
2.	Kelly MJ, Lloyd TD, Marshall D, et al. A snapshot of MDT working and patient mapping in the UK colorectal cancer centres in 2002 [J]. Colorectal Dis, 2003; 5(6): 577-581.
3.	de Geus-Oei LF, Vriens D, van Laarhoven HW, et al. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review [J]. J Nucl Med, 2009; 50 Suppl 1: 43S-54S.
4.	Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET [J]. Cancer Imaging, 2008; 8: 70-80.
5.	Savides TJ, Master SS. EUS in rectal cancer [J]. Gastrointest Endosc, 2002; 56(4 Suppl): S12-S18.
6.	Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089 [J]. J Clin Oncol, 2003; 21(15): 2912-2919.
7.	萬德森. 結直腸癌外科治療若干熱點問題 [J]. 中華腫瘤防治雜志, 2007; 14(8): 561.
8.	Burghardt J, Buess G. Transanal endoscopic microsurgery (TEM): a new technique and development during a time period of 20 years [J]. Surg Technol Int, 2005; 14: 131-137.
9.	Saha S, Dan AG, Viehl CT, et al. Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls [J]. Cancer Treat Res, 2005; 127: 105-122.
10.	Simunovic M, Smith AJ, Heald RJ. Rectal cancer surgery and regional lymph nodes [J]. J Surg Oncol, 2009; 99(4): 256-259.
11.	Moriya Y. Selection and techniques of surgical procedures based on the mode of cancer spread of rectal cancer [J]. Nippon Geka Gakkai Zasshi, 2005; 106(4): 302-305.
12.	VanMeter A, Signore M, Pierobon M, et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine [J]. Expert Rev Mol Diagn, 2007; 7(5): 625-633.
13.	Speer R, Wulfkuhle J, Espina V, et al. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy [J]. Cancer Genomics Proteomics, 2007; 4(3): 157-164.
14.	崔恒官, 曹秀峰. 手術為主的大腸癌綜合治療 [J]. 世界華人消化雜志, 2008; 16(16): 1774-1780.
15.	Yu J, Shannon WD, Watson MA, et al. Gene expression profiling of the irinotecan pathway in colorectal cancer [J]. Clin Cancer Res, 2005; 11(5): 2053-2062.
16.	Bandrés E, Zárate R, Ramirez N, et al. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy [J]. World J Gastroenterol, 2007; 13(44): 5888-5901.
17.	Pohl A, Lurje G, Manegold PC, et al. Pharmacogenomics and -genetics in colorectal cancer [J]. Adv Drug Deliv Rev, 2009; 61(5): 375-380.
18.	Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 [J]. J Clin Pharmacol, 2004; 44(8): 854-860.
19.	Marchetti P, Galla DA, Russo FP, et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line [J]. Anticancer Res, 2004; 24(1): 219-226.
20.	Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy [J]. J Clin Oncol, 2001; 19(23): 4298-4304.
21.	Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy [J]. J Clin Oncol, 2007; 25(10): 1247-1254.
22.	Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review [J]. Pharmacogenomics, 2008; 9(8): 1079-1099.
23.	Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumours [J]. Mol Med, 2009; 15(5-6): 183-191.
24.	Kim JS, Kim JM, Li S, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy [J]. Int J Radiat Oncol Biol Phys, 2006; 66(1): 195-200.
25.	Chang DZ, Kumar V, Ma Y, et al. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy [J]. J Hematol Oncol, 2009; 2: 18.
26.	Van Cutsem E, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [J]. J Clin Oncol, 2008; 26 (May 20 Suppl, Abstr 2).
27.	Bokemeyer C, Bondarenko I, Hartmann JT, et al. Korale-wski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [J]. J Clin Oncol, 2008; 26(May 20 Suppl; Abstr 4000).

1. 鄭樹主編. 結直腸腫瘤—基礎研究與臨床實踐 [M]. 北京: 人民衛生出版社， 2006: 3-4.
2. Kelly MJ, Lloyd TD, Marshall D, et al. A snapshot of MDT working and patient mapping in the UK colorectal cancer centres in 2002 [J]. Colorectal Dis, 2003; 5(6): 577-581.
3. de Geus-Oei LF, Vriens D, van Laarhoven HW, et al. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review [J]. J Nucl Med, 2009; 50 Suppl 1: 43S-54S.
4. Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET [J]. Cancer Imaging, 2008; 8: 70-80.
5. Savides TJ, Master SS. EUS in rectal cancer [J]. Gastrointest Endosc, 2002; 56(4 Suppl): S12-S18.
6. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089 [J]. J Clin Oncol, 2003; 21(15): 2912-2919.
7. 萬德森. 結直腸癌外科治療若干熱點問題 [J]. 中華腫瘤防治雜志, 2007; 14(8): 561.
8. Burghardt J, Buess G. Transanal endoscopic microsurgery (TEM): a new technique and development during a time period of 20 years [J]. Surg Technol Int, 2005; 14: 131-137.
9. Saha S, Dan AG, Viehl CT, et al. Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls [J]. Cancer Treat Res, 2005; 127: 105-122.
10. Simunovic M, Smith AJ, Heald RJ. Rectal cancer surgery and regional lymph nodes [J]. J Surg Oncol, 2009; 99(4): 256-259.
11. Moriya Y. Selection and techniques of surgical procedures based on the mode of cancer spread of rectal cancer [J]. Nippon Geka Gakkai Zasshi, 2005; 106(4): 302-305.
12. VanMeter A, Signore M, Pierobon M, et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine [J]. Expert Rev Mol Diagn, 2007; 7(5): 625-633.
13. Speer R, Wulfkuhle J, Espina V, et al. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy [J]. Cancer Genomics Proteomics, 2007; 4(3): 157-164.
14. 崔恒官, 曹秀峰. 手術為主的大腸癌綜合治療 [J]. 世界華人消化雜志, 2008; 16(16): 1774-1780.
15. Yu J, Shannon WD, Watson MA, et al. Gene expression profiling of the irinotecan pathway in colorectal cancer [J]. Clin Cancer Res, 2005; 11(5): 2053-2062.
16. Bandrés E, Zárate R, Ramirez N, et al. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy [J]. World J Gastroenterol, 2007; 13(44): 5888-5901.
17. Pohl A, Lurje G, Manegold PC, et al. Pharmacogenomics and -genetics in colorectal cancer [J]. Adv Drug Deliv Rev, 2009; 61(5): 375-380.
18. Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 [J]. J Clin Pharmacol, 2004; 44(8): 854-860.
19. Marchetti P, Galla DA, Russo FP, et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line [J]. Anticancer Res, 2004; 24(1): 219-226.
20. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy [J]. J Clin Oncol, 2001; 19(23): 4298-4304.
21. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy [J]. J Clin Oncol, 2007; 25(10): 1247-1254.
22. Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review [J]. Pharmacogenomics, 2008; 9(8): 1079-1099.
23. Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumours [J]. Mol Med, 2009; 15(5-6): 183-191.
24. Kim JS, Kim JM, Li S, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy [J]. Int J Radiat Oncol Biol Phys, 2006; 66(1): 195-200.
25. Chang DZ, Kumar V, Ma Y, et al. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy [J]. J Hematol Oncol, 2009; 2: 18.
26. Van Cutsem E, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [J]. J Clin Oncol, 2008; 26 (May 20 Suppl, Abstr 2).
27. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Korale-wski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [J]. J Clin Oncol, 2008; 26(May 20 Suppl; Abstr 4000).

《中國普外基礎與臨床雜志》

結直腸癌的個體化治療進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

結直腸癌的個體化治療進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料